Clinical Trials and Studies
Since its inception in 2008, ANZSA has been involved in more than 30 sarcoma-related studies and clinical trials, both locally and internationally.
Here you will find a list of research studies and clinical trials led or participated by ANZSA that are open for recruitment. If you are interested in taking part in a clinical trial, please discuss it with your doctor.
Information accurate as of 10 May 2019
SMOC+
A surveillance study utilising whole body magnetic resonance imaging and other surveillance procedures in people with germ line cancer gene mutations to investigate the prevalence and incidence of investigable lesions
Summary
A surveillance study utilising whole body magnetic resonance imaging (MRI) and other surveillance procedures in people with germ line cancer gene mutations to investigate the prevalence and incidence of investigable lesions.
Eligible Cohort
18-70 years old with known cancer risk gene pathogenic mutation carrier or family member at 50% risk of carrying a mutation
PHASE
N/A
RECRUITMENT TARGET
150
EXPECTED COMPLETION
2019
COUNTRY PI
Prof David Thomas
PARTICIPATING SITES
Monash Medical Centre - Clayton campus, St Vincent's Hospital - Darlinghurst, Prince of Wales Hospital - Randwick, Peter MacCallum Cancer Centre - Melbourne
CO-SPONSORS
ANZSA Johanna Sewell Sarcoma Research Grant, ANZSA/Cancer Australia (PdCCRS)
NORTH
A Phase II study of panobinostat in paediatric adolescent and young adult patients with solid tumours including osteosarcoma, malignant rhabdoid tumour and neuroblastoma
Summary
This is an open label, Phase II, multicentre study evaluating the anti-tumour activity of continuous, low dose of panobinostat in patients with refractory solid tumours stratified by primary histology into osteosarcoma, malignant rhabdoid tumour/atypical teratoid rabdoid tumour (MRT/ATRT) and neuroblastoma.
Eligible Cohort
Patients must be less than 40 years of age and must have been histologically diagnosed with osteosarcoma, neuroblastoma or MRT/ATRT at time of diagnosis or relapse
PHASE
Phase II
RECRUITMENT TARGET
60
EXPECTED COMPLETION
7 March 2022
COUNTRY PI
Dr Paul Wood, A/Prof Jayesh Desai, Prof David Ashley
PARTICIPATING SITES
Monash Children's Hospital, Starship Children's Hospital, Princess Alexandra Hospital, Royal Adelaide Hospital, Sydney Children's Hospital, Queensland Children's Hospital, Christchurch Hospital, Royal Children's Hospital, Chris O'Brien Lifehouse, Peter MacCallum Cancer Centre, Perth Children's Hospital
CO-SPONSORS
ANZCHOG, ANZSA
SARC032
A Phase II randomised controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab in patients with high-risk, localised soft tissue sarcoma of the extremity
Summary
This is a multicenter, randomised phase II trial with an initial safety run-in to test the safety and efficacy of neoadjuvant pembrolizumab with image-guided radiotherapy and adjuvant pembrolizumab compared to radiation therapy alone in patients with clinically localised extremity soft tissue sarcoma at high risk for developing metastatic disease (tumor size > 5 cm, intermediate- to high-grade; approximately 50% risk for distant disease at 2 years).
Eligible Cohort
18 years old and above
PHASE
Phase II
RECRUITMENT TARGET
110
EXPECTED COMPLETION
30 July 2025
COUNTRY PI
Prof Angela Hong
PARTICIPATING SITES
Australia - Peter MacCallum Cancer Centre, Chris O'Brien Lifehouse, Princess Alexandra Hospital; USA treating centres
CO-SPONSORS
ANZSA, Sarcoma Alliance for Research through Collaboration
rEECur
International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
Summary
rEECur is a Multi-Arm, Multi-Stage (MAMS) randomised phase II / phase III, open-label, international trial. Patients will be randomised at trial entry to receive one of up to four regimens.
Eligible Cohort
Ages 4-49, recurrent and refractory Ewing sarcoma
PHASE
Phase II and III
RECRUITMENT TARGET
525
EXPECTED COMPLETION
2018
COUNTRY PI
A/Prof Marianne Phillips, Dr Susie Bae
PARTICIPATING SITES
Perth Children's Hospital, Sydney Children's Hospital, Monash Children's Hospital, Queensland Children's Hospital, Starship Children's Hospital, Peter MacCallum Cancer Centre, Christchurch Hospital, Princess Alexandra Hospital, Prince of Wales Hospital
CO-SPONSORS
ANZSA, ANZCHOG (Medical Research Future Fund with CanTeen clinical trial grant)
ISKS
International Sarcoma Kindred Study
Summary
ISKS is a global genetic, biological, epidemiological and clinical resource for researchers to investigate important questions relating to the hereditary characteristics of sarcoma.
This project aims to establish an international database and biospecimen repository to be used as a clinical and research resource.
Eligible Cohort
Anybody with adult-onset sarcoma (over 15 years old) is eligible for the study. Family members may also be invited to participate if the person with sarcoma is under 45 years of age or there is a significant history of cancer in the family.
PHASE
N/A
RECRUITMENT TARGET
3000
EXPECTED COMPLETION
Ongoing
COUNTRY PI
Prof David Thomas, Dr Mandy Ballinger
PARTICIPATING SITES
Garvan Institute of Medical Research, Peter MacCallum Cancer Centre; together with international sites in France, USA, New Zealand, India, UK, Canada and South Korea
CO-SPONSORS
ANZSA, Rainbows for Kate Foundation, National Health and Medical Research Council, Victorian Cancer Agency, Cancer Australia, UK Sarcoma Trust, Liddy Shriver Sarcoma Initiative
PUBLICATIONS &
PRESENTATIONS
PRESENTATIONS
- Thomas DM, Ballinger ML. Etiologic, environmental and inherited risk factors in sarcomas. J Surg Oncol. 2015 Apr;111(5):490-5. doi: 10.1002/jso.23809. Epub 2014 Oct 21.
- Kate A. McBride; Nina Hallowell; Martin H.N. Tattersall ; Judy Kirk ; Mandy L. Ballinger; David M. Thomas; Gillian Mitchell & Mary-Anne Young. Timing and Context: Important considerations in the return of genetic results to research participants. Journal of Community Genetics 2015, DOI 10.1007/s12687-015-0231-7
- Ballinger ML, Mitchell G, Thomas DM. Surveillance recommendations for patients with germ-line TP53 mutations. Current Opinion in Oncology 2015, Vol 27 No 4 p332-337
The ANZSA national sarcoma database is a rich resource of data for Australia sarcoma clinical practice. The database was utilised for following studies.
As an ANZSA member, you are eligible to utilise data from our database for your sarcoma research or study. To find out more about our database and how you can utilise it, visit the Clinical Data page.
Information accurate as of 10 May 2019
AMOSS
Aggressive management of oligometastatic paediatric and adult sarcomas with either extirpative surgery and/or stereotactic ablative radiotherapy (SABR)
Summary
Patterns of care study describing the use of aggressive management of oligometastatic paediatric and adult sarcomas with either extirpative surgery and/or stereotactic ablative radiotherapy (SABR)
Eligible Cohort
Retrospective: Male or female, 48 months of age at the date of diagnostic biopsy
PHASE
N/A
RECRUITMENT TARGET
N/A
EXPECTED COMPLETION
2019
COUNTRY PI
Dr Phoebe Chidly, Dr Susie Bae, Dr Sarat Chander
PARTICIPATING SITES
Peter MacCallum Cancer Centre
CO-SPONSORS
ANZSA
Vascular Soft Tissue Sarcoma Study
Advances in the systemic treatment of angiosarcoma and other vascula-rich soft tissue sarcomas
Summary
Patterns of care study in describing systemic treatment of angiosarcoma and other vascula-rich soft tissue sarcomas.
Eligible Cohort
Retrospective: 18 years and older adults, diagnosed with advanced angiosarcoma or vascular-rich soft tissue sarcoma
PHASE
N/A
RECRUITMENT TARGET
N/A
EXPECTED COMPLETION
2019
COUNTRY PI
Dr Susie Bae, A/Prof Jayesh Desai
PARTICIPATING SITES
Peter MacCallum Cancer Centre, Royal Adelaide Hospital, Prince of Wales Hospital, Royal Prince Alfred Hospital, Sir Charles Gairdner Hospital, Canberra Hospital
CO-SPONSORS
ANZSA, Novartis
Advanced Soft Tissue Sarcoma Study
Real world treatment patterns and outcomes among patients with advanced soft tissue sarcoma (STS): A database analysis in Australia
Summary
A retrospective cohort study describing pattenrs of care in management of advanced soft tissue sarcoma (STS) at Australian sarcoma referral centres.
Eligible Cohort
Retrospective: Adult patients diagnosed with STS and seen at six sarcoma centres between 1/01/2010 and 31/12/2015 selected from ACCORD
PHASE
N/A
RECRUITMENT TARGET
N/A
EXPECTED COMPLETION
2019
COUNTRY PI
Dr Susie Bae, A/Prof Jayesh Desai
PARTICIPATING SITES
Peter MacCallum Cancer Centre, Royal Adelaide Hospital, Prince of Wales Hospital, Royal Prince Alfred Hospital, Sir Charles Gairdner Hospital, Canberra Hospital
CO-SPONSORS
ANZSA, Eli Lilly
RESAR
Retroperitoneal Sarcoma Registry (RESAR): prospective collection of primary retroperitoneal sarcoma patient's clinical, radiological and pathology data for the TransAtlantic Retroperitoneal Sarcoma Working Group
Summary
Prospective collection of primary retroperitoneal sarcoma patient's clinical, radiological and pathology data for the TransAtlantic Retroperitoneal Sarcoma Working Group
Eligible Cohort
Primary Retroperitoneal sarcoma operated on in the participating center; age>18 years at the time of the first treatment, histological confirmed diagnosis according to the WHO criteria done on biopsy or surgical specimen by dedicated sarcoma pathologist
PHASE
N/A
RECRUITMENT TARGET
2000
EXPECTED COMPLETION
2030
COUNTRY PI
Mr David Gyorki
PARTICIPATING SITES
Australia - Peter MacCallum Cancer Centre
CO-SPONSORS
ANZSA
Advanced Soft Tissue Sarcoma Study: Data Linkage
Treatment patterns, resource utilisation and healthcare costs among patients with advanced soft tissue sarcoma: A data linkage project using a Victorian cohort
Summary
A data linkage project using data from the Australian Comprehensive Cancer Outcomes and Research Database (ACCORD) linked with datasets from the Medicare Benefits Schedule (MBS), Pharmaceutical Benefits Scheme (PBS), National Death Index (NDI), Victoria admitted episode data set and Victoria Emergency Minimum dataset.
Eligible Cohort
Retrospective: Adult patients diagnosed with soft tissue sarcoma between 1/01/2010 and 31/12/2015 selected from ACCORD.
PHASE
N/A
RECRUITMENT TARGET
N/A
EXPECTED COMPLETION
2019
COUNTRY PI
Dr Susie Bae, A/Prof Jayesh Desai
PARTICIPATING SITES
Peter MacCallum Cancer Centre
CO-SPONSORS
ANZSA, Eli Lilly